American Association for Cancer Research
Browse
21598290cd190897-sup-226653_2_supp_6524453_qfy16z.pdf (6.67 MB)

Supplementary Methods, Figure S1-16, Table S1, S4-7, S9 from Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML

Download (6.67 MB)
journal contribution
posted on 2023-04-03, 22:22 authored by Sheng Li, Xiaowen Chen, Jiahui Wang, Cem Meydan, Jacob L. Glass, Alan H. Shih, Ruud Delwel, Ross L. Levine, Christopher E. Mason, Ari M. Melnick

Supplementary Methods, Figure S1-16, Table S1, S4-7, S9

Funding

NCI

LLS SCOR

National Institute of General Medical Sciences

The Jackson Laboratory Director's Innovation

NIH

History

ARTICLE ABSTRACT

Epigenetic allele diversity is linked to inferior prognosis in acute myeloid leukemia (AML). However, the source of epiallele heterogeneity in AML is unknown. Herein we analyzed epiallele diversity in a genetically and clinically annotated AML cohort. Notably, AML driver mutations linked to transcription factors and favorable outcome are associated with epigenetic destabilization in a defined set of susceptible loci. In contrast, AML subtypes linked to inferior prognosis manifest greater abundance and highly stochastic epiallele patterning. We report an epiallele outcome classifier supporting the link between epigenetic diversity and treatment failure. Mouse models with TET2 or IDH2 mutations show that epiallele diversity is especially strongly induced by IDH mutations, precedes transformation to AML, and is enhanced by cooperation between somatic mutations. Furthermore, epiallele complexity was partially reversed by epigenetic therapies in AML driven by TET2/IDH2, suggesting that epigenetic therapy might function in part by reducing population complexity and fitness of AMLs. We show for the first time that epigenetic clonality is directly linked to specific mutations and that epigenetic allele diversity precedes and potentially contributes to malignant transformation. Furthermore, epigenetic clonality is reversible with epigenetic therapy agents.This article is highlighted in the In This Issue feature, p. 1775

Usage metrics

    Cancer Discovery

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC